290 articles in this topic
A 5-year study finds bariatric surgery offers meaningful but attenuated weight loss in PWS kids versus lifestyle intervention alone.
A large real-world study finds post-transplant diabetes requiring insulin marks a high-risk metabolic phenotype with far worse graft and patient outcomes.
A newly identified mechanism shows how omega-3 fatty acids protect aging kidneys — and why low FFAR4 receptor expression accelerates kidney disease.
New JAMA research suggests reducing dietary protein may slow kidney disease progression and improve patient outcomes.
Blocking mTOR forces cancer cells to rewire cholesterol uptake and transport, revealing new drug targets when combined with rapamycin.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
A sweeping review of GLP-1 agonists, tirzepatide, and emerging hormone combos reshaping obesity treatment in 2025.
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
A new review links feline age-related obesity to SASP-driven chronic inflammation, offering translational insights for human metabolic disease.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
